JPMorgan analyst Jessica Fye reiterated an Overweight rating and $36.00 price target on Insmed (NASDAQ: INSM)The analyst comments "This morning ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Insmed (INSM) PT Raised to $67 at StifelMay 30, 2024 4:35 PM Insmed (INSM) PT Raised to $58 at UBSMay 29, 2024 5:37 AM Insmed (INSM) PT Raised to $68 at Truist SecuritiesMay 29, 2024 5:30 AM Insmed (INSM) PT Raised to $54 at Wolfe ResearchMay 29, 2024 5:25 AM Insmed (INSM) PT Raised to $62 at BofA SecuritiesMay 29, 2024 5:08 AM Insmed (INSM) PT Raised to $60 at Morgan StanleyMay 28, 2024 2:37 PM Goldman Sachs Reiterates Buy Rating on Insmed (INSM)May 28, 2024 1:27 PM Stifel Reiterates Buy Rating on Insmed (INSM)May 28, 2024 7:54 AM Evercore ISI Reiterates Outperform Rating on Insmed (INSM)May 28, 2024 7:36 AM Midday movers: Nvidia, Apple and GameStop rise; Tesla, DraftKings fallMay 28, 2024 7:29 AM Morgan Stanley Reiterates Overweight Rating on Insmed (INSM)May 28, 2024 7:16 AM Form 8-K INSMED Inc For: May 28May 28, 2024 6:31 AM Insmed (INSM) Reports Positive Topline Results from Landmark ASPEN Study of BrensocatibMay 28, 2024 6:31 AM Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with BronchiectasisMay 28, 2024 6:30 AM Increasing unusual call option volume: INSM ROST WDAY ZI BNED OKLO ASPN ICLN BJMay 28, 2024 4:58 AM Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with BronchiectasisMay 27, 2024 4:00 PM